ASCENT-04 analysis finds PFS2 advantage as an indicator of long-term clinical benefit
— ASCENT-04 analysis finds PFS2 advantage as an indicator of long-term clinical benefit
by Wayne Kuznar, Contributing Writer
June 2, 2026
• 3 min read
CHICAGO -- Sacituzumab govitecan (SG, Trodelvy) added to pembrolizumab (Keytruda) extended a surrogate measure of long-term clinical outcomes compared with chemotherapy plus pembrolizumab in patients with PD-L1-positive metastatic triple negative breast cancer (mTNBC), according to an analysis of the phase III ASCENT-04 trial.
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
AstraZeneca's triplet combo succeeds in some liver cancer patients
Daraxonrasib offers ‘transformational’ benefit in metastatic pancreatic cancer
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
Celcuity aims for broad FDA approval after positive breast cancer readout
ASCO 2026: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC - Pharmaceutical Technology
Akeso, Summit drug extends survival in closely watched lung cancer trial
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expressors
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target…
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in…
AstraZeneca on Monday reported data from a new combination study showing a combination of targeted and immunotherapies can…
Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone
CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based…
